§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇪🇺European Union Fees verified 12 September 2026	🇺🇸United States Fees verified 12 September 2026
Authority & dossier
Fee confirmation	Fees verified 12 September 2026	Fees verified 12 September 2026
Regulatory authority	EMA	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	None
Reference agencies	Not stated	Not stated
Lead pathway (timeline & fees), Centralised Procedure · New Drug Application, 505(b)(1)
Pathway name	Centralised Procedure	New Drug Application, 505(b)(1)
Approval timeline	210-277 days	304-365 days
Headline fee and pathway	EUR 865,200, Centralised Procedureconditional on other	USD 4,682,003, New Drug Application, 505(b)(1)conditional on other
Recurring charges	EUR 232,400 a year, per marketing authorisation, other applications	USD 442,213 a year, per product
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	6 designations	6 designations
Examples	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3	Priority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3
Post-approval lifecycle
Variations framework	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.	FDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-106 days	30-30 days
GCP standard	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Regulated	Free pricing
Reference pricing	Yes	No
HTA required	Yes	No
HTA body	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)	ICER (Institute for Clinical and Economic Review), independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

European UnionFees verified 12 September 2026
United StatesFees verified 12 September 2026

Regulatory authority

European UnionEMA
United StatesFDA

English submissions

European UnionYes
United StatesYes

CTD accepted

European UnionYes
United StatesYes

eCTD accepted

European UnionYes
United StatesYes

Reliance pathway

European UnionAvailable
United StatesNone

Reference agencies

European UnionNot stated
United StatesNot stated

Lead pathway (timeline & fees), Centralised Procedure · New Drug Application, 505(b)(1)

Pathway name

European UnionCentralised Procedure
United StatesNew Drug Application, 505(b)(1)

Approval timeline

European Union210-277 days
United States304-365 days

Headline fee and pathway

European UnionEUR 865,200, Centralised Procedureconditional on other
United StatesUSD 4,682,003, New Drug Application, 505(b)(1)conditional on other

Recurring charges

European UnionEUR 232,400 a year, per marketing authorisation, other applications
United StatesUSD 442,213 a year, per product

Local representative

European UnionRequired
United StatesNot required

Local manufacturing

European UnionNot required
United StatesNot required

GMP inspection

European UnionRequired
United StatesRequired

MAH & local presence

Local entity required

European UnionYes
United StatesNo

Local responsible person

European UnionYes
United StatesYes

RP role

European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

European Union6 designations
United States6 designations

Examples

European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval, Subpart H/E +3

Post-approval lifecycle

Variations framework

European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS), the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
United StatesFDA does not require periodic renewal of NDAs or BLAs, approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

European UnionAvailable
United StatesAvailable

Compassionate Use

European UnionAvailable
United StatesAvailable

Emergency Import

European UnionAvailable
United StatesAvailable

Parallel Import

European UnionPermitted
United StatesNot permitted

Clinical trials

CTA approval

European UnionRequired
United StatesRequired

Ethics approval

European UnionYes
United StatesYes

CTA timeline

European Union60-106 days
United States30-30 days

GCP standard

European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

European UnionRegulated
United StatesFree pricing

Reference pricing

European UnionYes
United StatesNo

HTA required

European UnionYes
United StatesNo

HTA body

European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)
United StatesICER (Institute for Clinical and Economic Review), independent, non-binding